Companies
why Day One Biopharmaceuticals Inc [DAWN] is a Good Choice for Investors After New Price Target of $28.62
Day One Biopharmaceuticals Inc [NASDAQ: DAWN] price plunged by -9.87 percent to reach at -$0.69. The one-year DAWN stock forecast points to a potential upside of 77.99. The average equity rating for DAWN stock is currently 1.22, trading closer to a bullish pattern in the